KalVista Pharmaceuticals Inc (NASDAQ: KALV) on Tuesday, soared 5.33% from the previous trading day, before settling in for the closing price of $10.89. Within the past 52 weeks, KALV’s price has moved between $7.30 and $17.28.
During the last 5-year period, the sales drop of Healthcare Sector giant was -17.63%. The company achieved an average annual earnings per share of 87.71%. With a float of $37.74 million, this company’s outstanding shares have now reached $50.34 million.
Let’s determine the extent of company efficiency that accounts for 270 employees.
KalVista Pharmaceuticals Inc (KALV) Breakdown of a Key Holders of the stock
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of KalVista Pharmaceuticals Inc is 25.31%, while institutional ownership is 91.93%. The most recent insider transaction that took place on Sep 08 ’25, was worth 115,537. In this transaction CHIEF EXECUTIVE OFFICER of this company sold 7,294 shares at a rate of $15.84, taking the stock ownership to the 395,189 shares. Before that another transaction happened on Aug 25 ’25, when Company’s Chief Commercial Officer sold 1,480 for $13.42, making the entire transaction worth $19,862. This insider now owns 32,291 shares in total.
KalVista Pharmaceuticals Inc (KALV) Recent Fiscal highlights
As on 10/31/2024, Multinational firm has announced its last quarter scores, in which it reported -0.91 earnings per share (EPS) for the period topping the consensus outlook (set at -0.91) by -0. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.92 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 87.71% per share during the next fiscal year.
KalVista Pharmaceuticals Inc (NASDAQ: KALV) Trading Performance Indicators
KalVista Pharmaceuticals Inc (KALV) is currently performing well based on its current performance indicators. A quick ratio of 5.37 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 405.43.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -4.00 and is forecasted to reach 0.91 in one year’s time.
Technical Analysis of KalVista Pharmaceuticals Inc (KALV)
Looking closely at KalVista Pharmaceuticals Inc (NASDAQ: KALV), its last 5-days average volume was 1.35 million, which is a jump from its year-to-date volume of 0.9 million. As of the previous 9 days, the stock’s Stochastic %D was 56.16%.
During the past 100 days, KalVista Pharmaceuticals Inc’s (KALV) raw stochastic average was set at 22.01%, which indicates a significant decrease from 79.10% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.51 in the past 14 days, which was lower than the 0.73 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $12.27, while its 200-day Moving Average is $12.29. However, in the short run, KalVista Pharmaceuticals Inc’s stock first resistance to watch stands at $11.96. Second resistance stands at $12.46. The third major resistance level sits at $13.16. If the price goes on to break the first support level at $10.76, it is likely to go to the next support level at $10.06. Now, if the price goes above the second support level, the third support stands at $9.56.
KalVista Pharmaceuticals Inc (NASDAQ: KALV) Key Stats
Market capitalization of the company is 579.77 million based on 50,523K outstanding shares. Right now, sales total 0 K and income totals -183,440 K. The company made 1,430 K in profit during its latest quarter, and -60,100 K in sales during its previous quarter.
